- MS drug found to benefit patients with more advanced disease The Pharmaceutical Journal
- Higher-dose ocrelizumab depletes more B cells but does not slow MS progression News-Medical
- Ocrelizumab cuts disability progression in primary progressive MS trial Medical Xpress